Iterum therapeutics plc (ITRM)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Revenue

-

37

276

530

715

869

789

0

0

0

-

Operating expenses:
Research and development

83,130

90,774

91,352

85,869

75,155

68,647

54,621

37,328

0

0

0

General and administrative

11,319

11,284

11,711

11,435

10,382

8,781

7,079

5,545

0

0

0

Total operating expenses

94,449

102,058

103,063

97,304

85,537

77,428

61,700

42,873

0

0

0

Operating loss

-94,449

-102,021

-102,787

-96,774

-84,822

-76,559

-60,911

-42,338

0

0

0

Interest expense, net

-3,353

-861

-752

-674

-615

-426

-6

178

0

0

0

Private placement transaction costs

0

-

-

-

-

-

-

-

-

-

-

Adjustments to fair value of derivatives

0

-

-

-

-

-

-

-

-

-

-

Other (expense) / income, net

34

196

393

673

464

401

302

139

0

0

0

Total other (expense) / income

-3,770

-665

-359

-1

-151

-25

296

317

0

0

0

Loss before income taxes

-98,219

-102,686

-103,146

-96,775

-84,973

-76,584

-60,615

-42,021

0

0

0

Income tax expense

431

444

601

606

517

472

354

323

0

0

0

Net loss and comprehensive loss

-98,650

-103,130

-103,747

-97,381

-85,490

-77,056

-60,969

-42,344

0

0

0

Net loss attributable to ordinary shareholders

-98,650

-103,130

-103,747

-97,381

-85,490

-77,056

-60,969

-42,344

0

0

0

Net loss per share attributable to ordinary shareholders – basic and diluted

-1.08

-1.58

-2.15

-1.93

-1.44

56.53

-1.77

-2.22

-61.36

-44.16

-39.44

Weighted average ordinary shares outstanding – basic and diluted

14,868

14,870

14,571

14,340

14,290

13,618

14,034

7,085

197

185

159